Polycan, a β-glucan from Aureobasidium pullulans SM-2001, mitigates ovariectomy-induced osteoporosis in rats

Jung,Mi  Young; Kim,Joo  Wan; Kim,Ki  Young; Choi,Seong  Hun; Ku,Sae  Kwang

doi:10.3892/etm.2016.3485

Polycan, a β-glucan from Aureobasidium pullulans SM-2001, mitigates ovariectomy-induced osteoporosis in rats

Authors:
- Mi Young Jung
- Joo Wan Kim
- Ki Young Kim
- Seong Hun Choi
- Sae Kwang Ku
View Affiliations

Affiliations: Department of Anatomy and Histology, College of Oriental Medicine, Daegu Haany University, Gyeongsan‑si, Gyeongsangbuk‑do 712‑715, Republic of Korea, Glucan Corp. Research Institute, Marine Bio‑Industry Development Center, Busan 619‑912, Republic of Korea
Published online on: June 27, 2016 https://doi.org/10.3892/etm.2016.3485
Pages: 1251-1262
Copyright: © Jung et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the protective effects of Polycan, a β-glucan from Aureobasidium pullulans SM‑2001, in a rat model of ovariectomy-induced osteoporosis. Ovariectomized (OVX) rats were orally administered 31.25, 62.5 or 125 mg/kg/day Polycan for 126 days, and alterations in body weight, bone mineral content, bone mineral density, failure load, histological profiles and histomorphometric indices were analyzed. In particular, serum levels of osteocalcin, bone-specific alkaline phosphatase (bALP), calcium and phosphorus, and the urine deoxypyridinoline/creatinine ratio, were measured. Furthermore, the femur, tibia and lumbar vertebrae were harvested from all rats, and histomorphometrical analyses were conducted in order to assess the mass and structure of the bones, and the rates of bone resorption and formation. One group of rats was treated with alendronate, which served as the reference drug. The results of the present study suggested that Polycan treatment was able to inhibit ovariectomy-induced alterations in bone resorption and turnover in a dose‑dependent manner. In addition, the serum expression levels of bALP and all histomorphometrical indices for bone formation were markedly increased in the Polycan-treated groups. These results indicated that Polycan was able to preserve bone mass and strength, and increase the rate of bone formation in OVX rats; thus suggesting that Polycan may be considered a potential effective anti-osteoporosis agent.

View Figures

View References

1	Sakai A, Nishida S, Okimoto N, Okazaki Y, Hirano T, Norimura T, Suda T and Nakamura T: Bone marrow cell development and trabecular bone dynamics after ovariectomy in ddy mice. Bone. 23:443–451. 1998. View Article : Google Scholar : PubMed/NCBI
2	Madureira MM, Ciconelli RM and Pereira RM: Quality of life measurements in patients with osteoporosis and fractures. Clinics (Sao Paulo). 6:1315–1320. 2012. View Article : Google Scholar
3	Melton LJ III, Chrischilles EA, Cooper C, Lane AW and Riggs BL: How many women have osteoporosis? JBMR Anniversary Classic. JMBR, Volume 7, Number 9, 1992. J Bone Miner Res. 20:886–892. 2005. View Article : Google Scholar : PubMed/NCBI
4	Rodan GA and Martin TJ: Therapeutic approaches to bone diseases. Science. 289:1508–1514. 2000. View Article : Google Scholar : PubMed/NCBI
5	Chen JS and Sambrook PN: Antiresorptive therapies for osteoporosis: A clinical overview. Nat Rev Endocrinol. 8:81–91. 2011. View Article : Google Scholar : PubMed/NCBI
6	Gowen M, Emery JG and Kumar S: Emerging therapies for osteoporosis. Expert Opin Emerg Drugs. 5:1–43. 2000.
7	Girotra M, Rubin MR and Bilezikian JP: Anabolic agents for osteoporosis: What is their likely place in therapy? Treat Endcrinol. 5:347–358. 2006. View Article : Google Scholar
8	Kalu DN: The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 15:175–191. 1991. View Article : Google Scholar : PubMed/NCBI
9	Frost HM and Jee WS: On the rat model of human osteopenias and osteoporoses. Bone Miner. 18:227–236. 1992. View Article : Google Scholar : PubMed/NCBI
10	Wronski TJ, Yen CF and Scott KS: Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats. J Bone Miner Res. 6:387–394. 1991. View Article : Google Scholar : PubMed/NCBI
11	Kimmel DB, Recker RR, Gallagher JC, Vaswani AS and Aloia JF: A comparison of iliac bone histomorphometric data in post-menopausal osteoporotic and normal subjects. Bone Miner. 11:217–235. 1990. View Article : Google Scholar : PubMed/NCBI
12	Ke HZ, Foley GL, Simmons HA, Shen V and Thompson DD: Long-term treatment of lasofoxifene preserves bone mass and bone strength and dose not adversely affect the uterus in ovariectomized rats. Endocrinology. 145:1996–2005. 2004. View Article : Google Scholar : PubMed/NCBI
13	Manolagas SC, Kousteni S and Jilka RL: Sex steroids and bone. Recent Prog Horm Res. 57:385–409. 2002. View Article : Google Scholar : PubMed/NCBI
14	Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC and Liberman UA: Alendronate Phase III Osteoporosis Treatment Study Group: Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 350:1189–1199. 2004. View Article : Google Scholar : PubMed/NCBI
15	Strewler GJ: Decimal point-osteoporosis therapy at the 10-year mark. N Engl J Med. 350:1172–1174. 2004. View Article : Google Scholar : PubMed/NCBI
16	Lauritzen DB, Balena R, Shea M, Seedor JG, Markatos A, Le HM, Toolan BC, Myers ER, Rodan GA and Hayes WC: Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats. J Bone Miner Res. 8:871–879. 1993. View Article : Google Scholar : PubMed/NCBI
17	McClung MR, Wasnich RD, Hosking DJ, Christiansen C, Ravn P, Wu M, Mantz AM, Yates J, Ross PD and Santora AC II: Early Postmenopausal Intervention Cohort Study: Prevention of postmenopausal bone loss: Six-year results from the early postmenopausal intervention cohort study. J Clin Endocrinol Metab. 89:4879–4885. 2004. View Article : Google Scholar : PubMed/NCBI
18	Bell NH: Advances in the treatment of osteoporosis. Curr Drug Targets Immune Endocr Metabol Disord. 1:93–102. 2001. View Article : Google Scholar : PubMed/NCBI
19	Boivin G and Meunier PJ: The mineralization of bone tissue: A forgotten dimension in osteoporosis research. Osteoporos Int. 14(Suppl 3): S19–S24. 2003.PubMed/NCBI
20	Shin HD, Yang KJ, Park BR, Son CW, Jang HJ and Ku SK: Antiosteoporotic effect of Polycan, beta-glucan from Aureobasidium, in ovariectomized osteoporotic mice. Nutrition. 23:853–860. 2007. View Article : Google Scholar : PubMed/NCBI
21	Song HB, Park DC, Do GM, Hwang SL, Lee WK, Kang HS, Park BR, Jang HJ, Son CW, Park EK, et al: Effect of exopolymers of Aureobasidium pullulans on improving osteoporosis induced in ovariectomized mice. J Microbiol Biotechnol. 16:37–45. 2006.
22	Park SO and Kim JM: Functional food for immune regulation - beta-glucan. Food Science and Industry. 45:39–47. 2012.
23	Estrada A, Yun CH, Van Kessel A, Li B, Hauta S and Laarveld B: Immunomodulatory activities of oat beta-glucan in vitro and in vivo. Microbiol Immunol. 41:991–998. 1997. View Article : Google Scholar : PubMed/NCBI
24	Bell S, Goldman VM, Bistrian BR, Arnold AH, Ostroff G and Forse RA: Effect of beta-glucan from oats and yeast on serum lipids. Crit Rev Food Sci Nutr. 39:189–202. 1999. View Article : Google Scholar : PubMed/NCBI
25	Seo HP, Kim JM, Shin HD, Kim TK, Chang HJ, Park BR and Lee JW: Production of β-1,3/1,6-glucan by Aureobasidium pullulans SM-2001. Korean J Bitechnol Bioeng. 17:376–380. 2002.
26	Lee HS, Cho HR, Moon SB, Shin HD, Yang KJ, Park BR, Jang HJ, Kim LS and Ku SK: Effect of β-glucan from Aureobasidium pullulans on rat rib fracture healing. Lab Anim Res. 24:39–44. 2008.
27	Han SY, Lee JR, Kwon YK, Jo MJ, Park SJ, Kim SC, Lee HS and Ku SK: Ostreae testa prevent ovariectomy-induced bone loss in mice by osteoblast activations. J Ethnopharmacol. 114:400–405. 2007. View Article : Google Scholar : PubMed/NCBI
28	Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM and Recker RR: Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res. 2:595–610. 1987. View Article : Google Scholar : PubMed/NCBI
29	Lorden JF and Caudle A: Behavioral and endocrinological effects of single injections of monosodium glutamate in the mouse. Neurobehav Toxicol Teratol. 8:509–519. 1986.PubMed/NCBI
30	Li B and Yu S: Genistein prevents bone resorption diseases by inhibiting bone resorption and stimulating bone formation. Biol Pharm Bull. 26:780–786. 2003. View Article : Google Scholar : PubMed/NCBI
31	Ladizesky MG, Cutrera RA, Boggio V, Somoza J, Centrella JM, Mautalen C and Cardinali DP: Effect of melatonin on bone metabolism in ovariectomized rats. Life Sci. 70:557–565. 2001. View Article : Google Scholar : PubMed/NCBI
32	Shim JG, Yeom SH, Kim HJ, Choi YW, Lee DI, Song KY, Kwon SH and Lee MW: Bone loss preventing effect of Sophorae Fructus on ovariectomized rats. Arch Pharm Res. 28:106–110. 2005. View Article : Google Scholar : PubMed/NCBI
33	Xu M, Dick IM, Day R, Randall D and Prince RL: Effects of a herbal extract on the bone density, strength and markers of bone turnover of mature ovariectomized rats. Am J Chin Med. 31:87–101. 2003. View Article : Google Scholar : PubMed/NCBI
34	Iwamoto J, Seki A, Takeda T, Sato Y, Yamada H and Yeh JK: Comparative therapeutic effects of alendronate and alfacalcidol on cancellous and cortical bone mass and mechanical properties in ovariectomized osteopenic rats. J Nutr Sci Vitaminol (Tokyo). 52:1–8. 2006. View Article : Google Scholar : PubMed/NCBI
35	Pavlik M: Measuring bone mineral content. Orthop Nurs. 10:39–43. 1991. View Article : Google Scholar : PubMed/NCBI
36	Tanaka S, Shimizu M, Debari K, Furuya R, Kawawa T and Sasaki T: Acute effects of ovariectomy on wound healing of alveolar bone after maxillary molar extraction in aged rats. Anat Rec. 262:203–212. 2001. View Article : Google Scholar : PubMed/NCBI
37	Syed Z and Khan A: Bone densitometry: Applications and limitations. J Obstet Gynaecol Can. 24:476–484. 2002. View Article : Google Scholar : PubMed/NCBI
38	Diez F: Guidelines for the diagnosis of osteoporosis by densitometric methods. J Manipulative Physiol Ther. 25:403–415. 2002. View Article : Google Scholar : PubMed/NCBI
39	Bilston LE, Little DG, Smith NC, Williams P and Briody J: Zoledronic acid improves the mechanical properties of normal and healing bone. Clin Biomech (Bristol, Avon). 17:716–718. 2002. View Article : Google Scholar : PubMed/NCBI
40	Heikkinen T, Puoliväli J and Tanila H: Effects of long-term ovariectomy and estrogen treatment on maze learning in aged mice. Exp Gerontol. 39:1277–1283. 2004. View Article : Google Scholar : PubMed/NCBI
41	Weinreb M, Patael H, Preisler O and Ben-Shemen S: Short-term healing kinetics of cortical and cancellous bone osteopenia induced by unloading during the reloading period in young rats. Virchows Arch. 431:449–452. 1997. View Article : Google Scholar : PubMed/NCBI
42	Verhaeghe J, Oloumi G, van Herck E, van Bree R, Dequeker J, Einhorn TA and Bouillon R: Effects of long-term diabetes and/or high-dose 17 beta-estradiol on bone formation, bone mineral density, and strength in ovariectomized rats. Bone. 20:421–428. 1997. View Article : Google Scholar : PubMed/NCBI
43	Gal-Moscovici A, Gal M and Popovtzer MM: Treatment of osteoporotic ovariectomized rats with 24,25(OH)2D3. Eur J Clin Invest. 35:375–379. 2005. View Article : Google Scholar : PubMed/NCBI
44	Andersson N, Lindberg MK, Ohlsson C, Andersson K and Ryberg B: Repeated in vivo determinations of bone mineral density during parathyroid hormone treatment in ovariectomized mice. J Endocrinol. 170:529–537. 2001. View Article : Google Scholar : PubMed/NCBI
45	da Paz LH, de Falco V, Teng NC, dos Reis LM, Pereira RM and Jorgetti V: Effect of 17beta-estradiol or alendronate on the bone densitometry, bone histomorphometry and bone metabolism of ovariectomized rats. Braz J Med Biol Res. 34:1015–1022. 2001. View Article : Google Scholar : PubMed/NCBI
46	Broulik PD, Rosenkrancová J, Růzicka P and Sedlácek R: Effect of alendronate administration on bone mineral density and bone strength in castrated rats. Horm Metab Res. 37:414–418. 2005. View Article : Google Scholar : PubMed/NCBI